Neidio i'r cynnwys
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文（繁體）
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Iaith
Pob Maes
Teitl
Awdur
Pwnc
Rhif Galw
ISBN/ISSN
Tag
Canfod
Uwch
Ranibizumab versus Bevacizuma...
Dyfynnu hwn
Anfonwch hwn fel neges destun
E-bostio hwn
Argraffu
Allforio Cofnod
Allforio i RefWorks
Allforio i EndNoteWeb
Allforio i EndNote
Permanent link
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Manylion Llyfryddiaeth
Prif Awduron:
Chakravarthy, U
,
Harding, S
,
Rogers, C
,
Downes, S
,
Lotery, A
,
Wordsworth, S
,
Reeves, B
Fformat:
Journal article
Cyhoeddwyd:
2012
Daliadau
Disgrifiad
Eitemau Tebyg
Dangos Staff
Eitemau Tebyg
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
gan: Chakravarthy, U, et al.
Cyhoeddwyd: (2012)
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
gan: Chakravarthy, U, et al.
Cyhoeddwyd: (2012)
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
gan: Dakin, H, et al.
Cyhoeddwyd: (2014)
Bevacizumab versus ranibizumab for neovascular age-related macular degeneration:a Meta-analysis
gan: Wen-Jie Wang, et al.
Cyhoeddwyd: (2015-02-01)
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
gan: Zhe-Li Liu, et al.
Cyhoeddwyd: (2013-04-01)